Impact of an irreversible β-galactosylceramidase inhibitor on the lipid profile of zebrafish embryos
© 2024 The Authors..
Krabbe disease is a sphingolipidosis characterized by the genetic deficiency of the acid hydrolase β-galactosylceramidase (GALC). Most of the studies concerning the biological role of GALC performed on Krabbe patients and Galc-deficient twitcher mice (an authentic animal model of the disease) indicate that the pathogenesis of this disorder is the consequence of the accumulation of the neurotoxic GALC substrate β-galactosylsphingosine (psychosine), ignoring the possibility that this enzyme may exert a wider biological impact. Indeed, limited information is available about the effect of GALC downregulation on the cell lipidome in adult and developing organisms. The teleost zebrafish (Danio rerio) has emerged as a useful platform to model human genetic diseases, including sphingolipidoses, and two GALC co-orthologs have been identified in zebrafish (galca and galcb). Here, we investigated the effect of the competitive and irreversible GALC inhibitor β-galactose-cyclophellitol (GCP) on the lipid profile of zebrafish embryos. Molecular modelling indicates that GCP can be sequestered in the catalytic site of the enzyme and covalently binds human GALC, and the zebrafish Galca and Galcb proteins in a similar manner. Accordingly, GCP inhibits the β-galactosylceramide hydrolase activity of zebrafish in vitro and in vivo, leading to significant alterations of the lipidome of zebrafish embryos. These results indicate that the lack of GALC activity deeply affects the lipidome during the early stages of embryonic development, and thereby provide insights into the pathogenesis of Krabbe disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Computational and structural biotechnology journal - 23(2024) vom: 21. Apr., Seite 1397-1407 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Guerra, Jessica [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Galactosylceramidase |
|---|
| Anmerkungen: |
Date Revised 11.04.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.csbj.2024.03.023 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370856503 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370856503 | ||
| 003 | DE-627 | ||
| 005 | 20240411232936.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240410s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.csbj.2024.03.023 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1372.xml |
| 035 | |a (DE-627)NLM370856503 | ||
| 035 | |a (NLM)38596316 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Guerra, Jessica |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of an irreversible β-galactosylceramidase inhibitor on the lipid profile of zebrafish embryos |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 11.04.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024 The Authors. | ||
| 520 | |a Krabbe disease is a sphingolipidosis characterized by the genetic deficiency of the acid hydrolase β-galactosylceramidase (GALC). Most of the studies concerning the biological role of GALC performed on Krabbe patients and Galc-deficient twitcher mice (an authentic animal model of the disease) indicate that the pathogenesis of this disorder is the consequence of the accumulation of the neurotoxic GALC substrate β-galactosylsphingosine (psychosine), ignoring the possibility that this enzyme may exert a wider biological impact. Indeed, limited information is available about the effect of GALC downregulation on the cell lipidome in adult and developing organisms. The teleost zebrafish (Danio rerio) has emerged as a useful platform to model human genetic diseases, including sphingolipidoses, and two GALC co-orthologs have been identified in zebrafish (galca and galcb). Here, we investigated the effect of the competitive and irreversible GALC inhibitor β-galactose-cyclophellitol (GCP) on the lipid profile of zebrafish embryos. Molecular modelling indicates that GCP can be sequestered in the catalytic site of the enzyme and covalently binds human GALC, and the zebrafish Galca and Galcb proteins in a similar manner. Accordingly, GCP inhibits the β-galactosylceramide hydrolase activity of zebrafish in vitro and in vivo, leading to significant alterations of the lipidome of zebrafish embryos. These results indicate that the lack of GALC activity deeply affects the lipidome during the early stages of embryonic development, and thereby provide insights into the pathogenesis of Krabbe disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Galactosylceramidase | |
| 650 | 4 | |a Krabbe disease | |
| 650 | 4 | |a Lipidomics | |
| 650 | 4 | |a Molecular modeling | |
| 650 | 4 | |a Zebrafish | |
| 700 | 1 | |a Belleri, Mirella |e verfasserin |4 aut | |
| 700 | 1 | |a Paiardi, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Tobia, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Capoferri, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Corli, Marzia |e verfasserin |4 aut | |
| 700 | 1 | |a Scalvini, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Ghirimoldi, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Manfredi, Marcello |e verfasserin |4 aut | |
| 700 | 1 | |a Wade, Rebecca C |e verfasserin |4 aut | |
| 700 | 1 | |a Presta, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Mignani, Luca |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Computational and structural biotechnology journal |d 2012 |g 23(2024) vom: 21. Apr., Seite 1397-1407 |w (DE-627)NLM218960549 |x 2001-0370 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2024 |g day:21 |g month:04 |g pages:1397-1407 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.csbj.2024.03.023 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2024 |b 21 |c 04 |h 1397-1407 | ||